

- **Name:** Haley Ellis
 - **Current Position & Affiliation:** Medical Oncologist, Massachusetts General Hospital
 - **Country:** USA
-

- **Educational Background:**

- Medical Oncology Fellowship, Dana-Farber Cancer Institute
- Internal Medicine Residency, Washington University in St. Louis
- MD (Honors), University College Dublin
- BSc (Honors) in Molecular and Cell Biology, McGill University

- **Professional Experience:**

- Attending Physician and Assistant in Medicine, Massachusetts General Hospital
- Clinical Instructor, Harvard Medical School
- Research Fellow, Massachusetts General Hospital / Harvard Medical School
- Clinician-Scientist Training and Research Scholar, Washington University in St. Louis
- Research Fellow, Memorial Sloan Kettering Cancer Center

- **Professional Organizations:**

- Gallbladder Cancer Scientific & Medical Advisory Board
- International Cholangiocarcinoma Research Network Data Committee

- **Main Scientific Publications:**

- Vijay V*, Karisani N*, Shi L, Hung YH, Vu P, Kattel P, Kenney L, Merritt J, Adil R, Wu Q, Zhen Y, Morris R, Kreuzer J, Kathiresan M, Herrera Lopez XI, **Ellis H**, Gritti I, Lecorgne L, Farag I, Popa A, Shen W, Kato H, Xu Q, Balasooriya ER, Wu MJ, Wan J, Kondo H, Chaturantabut S, Raghavan S, Hall MD, Patnaik S, Shen M, Kelley RK, Cleary JM, Lawrence MS, Root DE, Patra KC, Silveira VS, Benes CH, Deshpande V, Juric J, Sellers WR, Ferrone CR, Haas W, Vazquez F[†], Getz G[†], Bardeesy N[†]. Generation of a biliary tract cancer cell line atlas identifies molecular subtypes and therapeutic targets. *Cancer Discov.* 2025 May.
- **Ellis H**, Braconi C, Valle JW, Bardeesy N. Cholangiocarcinoma targeted therapies: Mechanisms of action and resistance. *Am J Pathol.* 2025 Mar;195(3):437-452.
- Riedl JM*, Fece de la Cruz F*, Lin JJ, Parseghian C, Kim JE, Matsubara H, Barnes

- H, Caughey B, Norden B, Morales A, Kushner E, Ehnstrom S, Nakamura H, Patel PS, **Ellis H**, Pappas L, Varkaris A, Gainor JF, Kopetz S, Klempner SJ, Parikh AR, Hata AN, Heist RS, Corcoran RB. Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS G12C inhibitors. *Ann Oncol*. 2025 Feb:S0923-7534(25)00052-3.
- **Ellis H**, Goyal L. Are FGFR fusions and mutations the next tumor-agnostic targets in oncology? *JCO Precis Oncol*. 2024 May;8:e2400113.
 - Balasooriya ER*, Wu Q*, **Ellis H**, Zhen Y, Norden BL, Corcoran RB, Mohan A, Martin E, Franovic A, Tyhonas J, Lardy M, Grandinetti KB, Pelham RJ, Soroceanu L, Silveira VS[†], Bardeesy N[†]. The irreversible FGFR inhibitor KIN-3248 overcomes FGFR2 kinase domain mutations. *Clin Cancer Res*. 2024 May;30(10):2181-2192.
 - Zhen Y, Liu K, Shi L, Shah S, Xu Q, **Ellis H**, Balasooriya ER, Kreuzer J, Morris R, Baldwin AS, Juric D, Haas W, Bardeesy N. FGFR inhibition blocks NF-κB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma. *Nat Comm*. 2024 May;15(1):3805.
 - Wu Q*, **Ellis H***, Siravegna G, Michel AG, Norden BL, Fecce de la Cruz F, Balasooriya ER, Zhen Y, Silveira VS, Che J, Corcoran RB[†], Bardeesy N[†]. Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma. *Clin Cancer Res*. 2024 Jan;30(1):198-208.
 - **Ellis H**, Raghavan S, Wolpin BM, Cleary JM. How we treat advanced biliary tract cancers in the second-line setting. *Clin Adv Hematol Oncol*. 2023 Jan;21(1):35-42.
 - Castel P, **Ellis H**, Bago R, Toska E, Razavi P, Carmona FJ, Kannan S, Verma CS, Dickler M, Chandarlapaty S, Brogi E, Alessi DR, Baselga J[†], Scaltriti M[†]. PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3Ka inhibition. *Cancer Cell*. 2016 Aug;30(2):229-42.
 - Juric D*, Castel P*, Griffith M, Griffith OL, Won HH, **Ellis H**, Ebbesen SH, Ainscough BJ, Ramu A, Iyer G, Shah RH, Huynh T, Mino-Kenudson M, Sgroi D, Isakoff S, Thabet A, Elamine L, Solit DB, Lowe SW, Quadt C, Peters M, Derti A, Schegel R, Huang A, Mardis ER, Berger MF[†], Baselga J[†], Scaltriti M[†]. Convergent loss of PTEN leads to clinical resistance to a PI3Ka inhibitor. *Nature*. 2015 Feb;518(7538):240-4.